PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
57.28
-0.73 (-1.26%)
At close: Sep 5, 2025, 4:00 PM
57.26
-0.02 (-0.03%)
After-hours: Sep 5, 2025, 6:53 PM EDT
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $178.88M in the quarter ending June 30, 2025, a decrease of -4.19%. This brings the company's revenue in the last twelve months to $1.76B, up 96.00% year-over-year. In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%.
Revenue (ttm)
$1.76B
Revenue Growth
+96.00%
P/S Ratio
2.52
Revenue / Employee
$1,879,584
Employees
939
Market Cap
4.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PTCT News
- 16 days ago - PTC Therapeutics Stock Is Stuck In A Multi-Year Slump - Benzinga
- 16 days ago - PTC Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 17 days ago - PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst - Seeking Alpha
- 18 days ago - PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns - Benzinga
- 18 days ago - US FDA declines to approve PTC Therapeutics' rare genetic disorder drug - Reuters
- 18 days ago - PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - PRNewsWire
- 4 weeks ago - PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - PRNewsWire